Entry

D11160                      Drug

Name

Caplacizumab (USAN/INN);
Caplacizumab (genetical recombination) (JAN);
Caplacizumab-yhdp;
Cablivi (TN)

Product

CABLIVI (Genzyme Corporation)

Formula

C1213H1891N357O380S10

Exact mass

27858.6828

Mol weight

27875.8075

Sequence

EVQLVESGGG LVQPGGSLRL SCAASGRTFS YNPMGWFRQA PGKGRELVAA ISRTGGSTYY
PDSVEGRFTI SRDNAKRMVY LQMNSLRAED TAVYYCAAAG VRAEDGRVRT LPSEYTFWGQ
GTQVTVSSAA AEVQLVESGG GLVQPGGSLR LSCAASGRTF SYNPMGWFRQ APGKGRELVA
AISRTGGSTY YPDSVEGRFT ISRDNAKRMV YLQMNSLRAE DTAVYYCAAA GVRAEDGRVR
TLPSEYTFWG QGTQVTVSS
(Disulfide bridge: 22-96, 153-227)

Type

Peptide

Class

Blood modifier agent
DG01950 Antithrombotic agent
DG01712 Antiplatelet agent

Remark

ATC code:

B01AX07

Product:

D11160<US>

Efficacy

Platelet aggregation inhibitor, Anti-vWF antibody

Disease

Acquired thrombotic thrombocytopenic purpura [DS:H00225]

Comment

Monoclonal antibody
Treatment of thrombotic thrombocytopenic purpura, thrombosis

Target

VWF [HSA:7450] [KO:K03900]

Pathway

hsa04610

Complement and coagulation cascades

hsa04611

Platelet activation

Interaction

Brite

Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
B BLOOD AND BLOOD FORMING ORGANS
  B01 ANTITHROMBOTIC AGENTS
   B01A ANTITHROMBOTIC AGENTS
    B01AX Other antithrombotic agents
     B01AX07 Fondaparinux
      D11160  Caplacizumab (USAN/INN) <US>
USP drug classification [BR:br08302]
Blood Products and Modifiers
  Platelet Modifying Agents
   Platelet Modifying Agents, Other
    Caplacizumab
     D11160  Caplacizumab (USAN/INN)
Drug groups [BR:br08330]
Blood modifier agent
  DG01950  Antithrombotic agent
   DG01712  Antiplatelet agent
    D11160  Caplacizumab
Target-based classification of drugs [BR:br08310]
Not elsewhere classified
  Organismal systems
   Complement and coagulation
    VWF
     D11160  Caplacizumab (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
  D11160
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
  D11160
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
  D11160

Other DBs

CAS:	915810-67-2

PubChem:

376219084